Anaptysbio (ANAB) Cash & Equivalents (2016 - 2026)

Anaptysbio has reported Cash & Equivalents for 11 years, with the latest figure at $248.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 151.9% year-over-year to $248.5 million; the trailing twelve-month figure through Mar 2026 stood at $248.5 million (up 151.9% YoY), and the FY2025 full-year result was $238.2 million, up 93.53% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $248.5 million, up from $238.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $248.5 million in Q1 2026, with the low at $26.3 million in Q3 2023.
• Historically, Cash & Equivalents has averaged $102.3 million across 5 years, with a median of $71.8 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Equivalents sank 85.62% — and 2024, when it jumped 628.58%.
• Anaptysbio's Cash & Equivalents stood at $71.3 million in 2022, then sank by 49.56% to $36.0 million in 2023, then jumped by 242.22% to $123.1 million in 2024, then jumped by 93.53% to $238.2 million in 2025, then rose by 4.31% to $248.5 million in 2026.
• The last three Cash & Equivalents figures came in at $248.5 million (Q1 2026), $238.2 million (Q4 2025), and $109.8 million (Q3 2025), per Business Quant data.